- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2021 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Diabetes
The Endocrinology Network® Diabetes clinical resource center offers readers the very latest news and information related to diabetes management. Including content related to type 1 diabetes, type 2 diabetes, and gestational diabetes, the diabetes clinical resource center hosts information on FDA approvals, the latest studies, and practice updates for clinicians practicing in the field of endocrinology.
Future Directions for the Use of Biosimilars in Diabetes
December 01, 2021
Drs Thomas C. Blevins and Diana Isaacs share insight on unmet needs and the future treatment landscape of biosimilars in the treatment of patients with diabetes.
Challenges to Biosimilar Adoption of Insulin Glargine-yfgn
December 01, 2021
Thomas C. Blevins, MD, ECNU, FACE, FNLA, leads the discussion on potential challenges to the adoption of biosimilars in clinical practice, such as for insulin glargine-yfgn in diabetes management, and discusses the importance of patient and provider education.
Impact of Interchangeable Insulin Biosimilars on Cost of Biologics
December 01, 2021
Thomas C. Blevins, MD, ECNU, FACE, FNLA, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss the impact of interchangeable insulin biosimilars on biologic products in the marketplace for diabetes management.
Results of INSTRIDE Studies for Diabetes Management
December 01, 2021
Experts in diabetes management discuss data from key clinical trials—INSTRIDE 1, INSTRIDE 2, and INSTRIDE 3—and evaluate the use of insulin glargine-yfgn as an interchangeable product with biologics.
Role of Interchangeable Biosimilars in the Management of Diabetes
December 01, 2021
Thomas C. Blevins, MD, ECNU, FACE, FNLA, provides an overview of biosimilars and discusses interchangeability status among biosimilars such as for insulin glargine-yfgn for the management of diabetes.
Basal Insulin Therapies for Diabetes Management
December 01, 2021
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Thomas C. Blevins, MD, ECNU, FACE, FNLA, review FDA-approved basal insulins for the management of diabetes.
Transgender Individuals at Increased Risk of Type 2 Diabetes, Not Linked to Hormone Therapy
December 01, 2021
A study from Emory University details the risk of developing type 2 diabetes among transgender individuals compared to their cisgender counterparts and takes a deeper dive into the influence of gender-affirming hormone therapy on this risk
Endocrine Month in Review: November 2021
November 27, 2021
November's endocrine month in review features stories on the Build Back Better Act, a recent review from the IOF, data from Kidney Week 2021, and more.
Diabetes Community Celebrates Build Back Better Act, Potential for $35 Insulin Caps
November 24, 2021
Diana Isaacs, PharmD, discusses the Build Back Better Act, the potential impact of a monthly spending cap on insulin, and reflects on the progress that has been made in regard to insulin affordability during the 100-year anniversary of the discovery of insulin.
Self-Isolation During Pandemic Limited Access to Medication, Impacted Glucose Control In Patients with Diabetes
November 22, 2021
An analysis of survey data from patients in multiple countries provides clinicians with an overview of the effects of self-isolation during the COVID-19 pandemic on diabetes management, including access to insulin and blood glucose fluctuations.